Educational evidence summaries. No dosing, sourcing, or treatment instructions.
The CJC Axis Editorial Team prepares evidence-led explainers on growth hormone-releasing peptides and clearly separates measured outcomes from proposed benefits.
42 published notesAn evidence-led GHRH Analogues review focused on sampling and assay timing, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamAn evidence-led GHRH Analogues review focused on compounding evidence, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamAn evidence-led GHRH Analogues review focused on fda status explained, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamA regulatory history of sermorelin, including former Geref products, discontinuation and the status of compounded preparations.
Reviewed by CJC Axis Editorial TeamAn evidence-led GHRH Analogues review focused on product identity and purity, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamAn evidence-led GHRH Analogues review focused on gh and igf-1 biomarkers, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamAn evidence-led Hexarelin review focused on adverse-event reporting, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamAn evidence-led Hexarelin review focused on population generalizability, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamAn evidence-led GHRP-6 review focused on wada and sport rules, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial Team